Journal of Leukocyte Biology eBioscience full spectrum cell analysis
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

A more recent version of this article appeared on November 1, 2007

Published online before print August 3, 2007
This Article
Right arrow Full Text (Reprint (PDF))
Right arrow All Versions of this Article:
jlb.0507296v1
82/5/1083    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reynolds, A. D.
Right arrow Articles by Mosley, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reynolds, A. D.
Right arrow Articles by Mosley, R. L.
© by The Society for Leukocyte Biology
Journal of Leukocyte Biology, doi:10.1189/jlb.0507296

Received for publication May 10, 2007.
Revised July 8, 2007.
Accepted for publication July 9, 2007.

Article

Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson’s disease

Ashley D. Reynolds *{dagger}, Rebecca Banerjee *{dagger}, Jianou Liu *{dagger}, Howard E. Gendelman *{dagger}{ddagger}@, and R. Lee Mosley *{dagger}

*Center for Neurovirology and Neurodegenerative Disorders, Departments of {dagger}Pharmacology and Experimental Neuroscience and {ddagger}Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA

@ To whom correspondence should be addressed. E-mail: hegendel{at}unmc.edu.


  Abstract

Progressive loss of dopaminergic neurons in the substantia nigra pars compacta and their terminal connections in the striatum are central features in Parkinson’s disease (PD). Emerging evidence supports the notion that microglia neuroinflammatory responses speed neurodegenerative events. We demonstrated previously that this can be slowed by adoptive transfer of T cells from copolymer-1-immunized mice administered to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) recipients. The cellular basis for this neuroprotective response was the CD4+ T cell population, suggesting involvement of CD4+CD25+ regulatory T cells (Tregs), cells known to suppress immune activation and maintain immune homeostasis and tolerance. We show for the first time that adoptive transfer of CD3-activated Tregs to MPTP-intoxicated mice provides greater than 90% protection of the nigrostriatal system. The response was dose-dependent and paralleled modulation of microglial responses and up-regulation of the glial cell-derived neurotrophic factor and TGF-{beta}. It is interesting that adoptive transfer of effector T cells showed no significant neuroprotective activities. Tregs were found to mediate neuroprotection through suppression of microglial responses to stimuli, including aggregated, nitrated {alpha}-synuclein. Moreover, Treg-mediated suppression was also operative following removal of Tregs from culture prior to stimulation. This neuroprotection was achieved through modulation of microglial oxidative stress and inflammation. As Tregs can be modulated in vivo, these data strongly support the use of such immunomodulatory strategies to treat PD.

Key Words: neurodegeneration • neuroprotection • inflammation • microglia






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2007 by the Society for Leukocyte Biology.